Justin S. Platt

Justin S. Platt is a partner at Goodwin. Justin’s practice focuses on health sciences, capital markets, and corporate matters. He specifically represents issuers and underwriters in initial public offerings, public and private offerings of debt, equity, preferred securities, and a variety of other corporate finance transactions.

Recent Life Science Transactions

• Represented Rapport Therapeutics, Inc. in its $174.4 million initial public offering and concurrent private placement
• Represented Metagenomi, Inc. in its $93.75 million initial public offering
• Represented Century Therapeutics, Inc. in its $242.7 million initial public offering*
• Represented Cognition Therapeutics, Inc. in its $45.2 million initial public offering and additional follow-on offerings*
• Represented Kymera Therapeutics, Inc. in its $258 million public follow-on offering
• Represented Century Therapeutics, Inc. in its $60 million private placement
• Represented underwriters in connection with $75 million public offering for Taysha Gene Therapies, Inc.
• Represented underwriters in connection with $20 million public offering for Aileron Therapeutics, Inc.
• Represented SWK Holdings Corporation in its inaugural registered underwritten debt offering of approximately $33 million in 9.00% Senior Notes due 2027
• Represented Baudax Bio, Inc. in a series of public offerings, warrant exchanges and RDOs totaling more than $50 million*
• Represented Ocugen, Inc. in its $53.5 million public follow-on offering*
• Represented Tela Bio, Inc. in multiple underwritten follow-on offerings totaling approximately $85 million* 
• Represented Athenex, Inc. in it $66 million initial public offering*
• Represented underwriters in multiple equity offerings and at-the-market offerings for life science issuers*
• Represented Renovacor, Inc. in its sale to Rocket Pharmaceuticals, Inc.*
• Represented Renovacor, Inc. in its merger with SPAC Chardan Healthcare Acquisitions 2 Corp. and concurrent private placement*
• Represented Century Therapeutics, Inc. in its collaboration and license transaction with Bristol-Myers Squibb Company*
• Represented GlaxoSmith Kline in connection with its license transaction with Spero Therapeutics, Inc.*

Transactions for other Industries

• Represented Athene Holdings Ltd. in its $1.24 billion initial public offering, multiple follow-on equity offerings, and inaugural senior notes offering*
• Represented underwriters in connection with $162.1 million offering for VSE Corporation
• Represented the underwriters in connection with an acquisition financing for Sempra Energy including a sale by the company of (i) $2.5 billion of common stock through a primary issuance and entry into forward sale agreements, (ii) $1.5 billion of 6% mandatory convertible preferred stock, and (iii) $5 billion of senior fixed and floating rate notes*
• Represented the underwriters in connection with an acquisition financing for Conagra Brands, Inc. which included the sale of $575 million of common stock and $7.025 billion of senior fixed and floating rate notes*
• Represented underwriters in connection with Franklin Financial Network’s $55.4 million initial public offering subsequent $40 million subordinated notes offering*
• Represented the underwriters in public and private equity, debt, and preferred stock transactions for over a dozen issuers in a variety of industries*

*Denotes experience prior to joining Goodwin